Scientific Program to download: Progam PDF

Thursday, January 23, 2020

DINNER BUFFET MEETING (registration required)
19:00              Welcome
19:15–20:00    Diagnostic workup of MGUS, SMM and MM, and recommendations for follow-up & question and answers
Joan Bladé


Friday, January 24, 2020



08:15–08:20    Welcome
Heinz Ludwig and Jesús San-Miguel
08:20–08:45    Molecular pathogenesis of multiple myeloma
Niccolò Bolli
08:45–09:10    Molecular profiling of MM, clinical relevance and prospects for the future
Charlotte Pawlyn
09:10–09:35    Next generation flow in monoclonal gammopathies
Bruno Paiva
09:35–10:05    Expert discussion: How to implement this information into clinical practice?
Moderator: Jesus San Miguel
Participants: Charlotte Pawlyn, Bruno Paiva, Niccolò Bolli
  • What induces progression?
  • What do we know about the interplay between immune environment and epigenetics?
  • Does immune profiling at baseline inform about prognosis?
  • Is MRD assessment ready for use in clinical practice?
  • Questions from audience
10:05–10:35    Coffee Break
10:35–11:25    Workshops
  • Renal disease in multiple myeloma: Pathophysiology and treatment Mark Cook
  • Imaging and Management of myeloma bone disease Evangelos Terpos
  • What you need to know about cytogenetic and molecular risk factors in MM Dirk Hose
11:25–11:50    Smoldering myeloma – risk stratification and management
María-Victoria Mateos
11:50–12:20    Keynote lecture: Aiming for cure of MM. Recent milestones and strategies for the future
Jesus San Miguel
12:2012:45    Expert discussion: Recent progress and where to go to?
Moderator: Jesus San Miguel
Participants: María-Victoria Mateos, Philippe Moreau
  • Should novel cellular immune therapies be integrated in first line treatment
  • Personalized treatment selection – a realistic expectation?
  • Which predictive algorithm should be used in SMM?
  • Questions from audience

12:45–13:45    Lunch 

13:45–15:15    Mini-Symposium – The transplant eligible patient
13:45–14:10    Is transplant needed for all TE patients?
Philippe Moreau
14:10–14:35    Established and new options for maintenance therapy
Michele Cavo
14:35–15:00   Expert discussion: Management of TE patients seems to be straight forward, but does this apply to every patient?
Moderator: Philippe Moreau
Participants: Michele Cavo, María-Victoria Mateos, Jesus San Miguel
  • Is splitting cycles to induction and consolidation superior to an equal number of cycles given upfront?
  • Is there any evidence suggesting switching to another regimen before ASCT if the patient does not respond to initial therapy?
  • First line or delayed ASCT? Any preference depending on patient’s risk?
  • What is the optimal maintenance therapy for HR-disease?
  • Questions from the audience
15:00–15:30    Coffee Break
15:30–16:20    Workshops (programme repeated)
16:20–17:30    Mini-Symposium – Management of transplant-non eligible patients
16:20–16:45    Treatment options for elderly fit patients
Kwee Yong
16:45–17:10    Management of elderly, unfit and frail patients
Alessandra Larocca
17:10–17:30    Expert discussion: Management of elderly patients
Moderator: Heinz Ludwig
Participants: Kwee Yong, Alessandra Larocca
  • How to improve induction therapy for TNE patients?
  • Optimal approach in frail patients?
  • Is maintenance therapy a valuable option for elderly patients?
  • Strategies for patients not responding to induction?
  • Questions from the audience


Saturday, January 25, 2020


BREAKFAST MEETING (registration required)
07:45–08:15    CAR-T cells
Mohamad Mohty


08:30–09:50    Mini-Symposium – Management of high-risk and relapsed patients
    08:30–08:55    Management of genetically defined high-risk MM
   Pieter Sonneveld
    08:55–09:20    Extramedullary disease and plasma cell leukemia
   Francesca Gay
    09:20–09:50    Management of patients with relapsed disease
   Heinz Ludwig
09:50–10:15    Expert discussion: How to improve treatment inn HR and RRMM patients?
Moderators: Heinz Ludwig
Participants: Pieter Sonneveld, Francesca Gay
  • Can we overcome the negative impact of HR disease with presently available approaches
  • Is there a role for aggressive lymphoma type treatment in extramedullary disease?
  • Refractoriness – a basket with widely different conditions. How to sort this out?
  • Questions from the audience
10:15–10:35    Coffee break
10:35–11:00    Novel drug targets and therapies
Enrique Ocio

11:00–11:25    BiTEs, antibody conjugates and cellular immunotherapy
Hermann Einsele
11:25–11:55   Expert discussion: Novel treatment approaches
Moderator: Hermann Einsele
Participants: Mohamad Mohty, Enrice Ocio
  • Varying clonal load, multiple upregulated pathways - is there any realistic chance for long-term success of targeted therapies in MM?
  • What is the optimal BM microenvironment for immune therapies
  • Progress in cellular therapies is much faster than the time consuming approval process – any clues to overcome this hurdle?
  • Questions from the audience
11:55–12:20    New developments in amyloidosis
Giampaolo Merlini
12:20–12:30   Closure of the meeting
Heinz Ludwig
12:30–13:30    Lunch 
Program and themes are subject to change!